Financial Position - Total assets as of September 30, 2025, amounted to $676,031[11] - Current liabilities totaled $707,710, with accrued offering costs of $651,031[11] - As of September 30, 2025, the Company had no cash and a working capital deficit of $682,710[41] - Following the IPO, the Company had cash of $1,384,527 and working capital of $931,057[42] - A total of $345,000,000 was placed in the Trust Account following the Initial Public Offering and private placement[110] Initial Public Offering (IPO) - The company completed its Initial Public Offering on December 12, 2025, raising gross proceeds of $345,000,000 from the sale of 34,500,000 units at $10.00 per unit[24] - The Company sold 34,500,000 Units in its Initial Public Offering at a price of $10.00 per Unit, including the full exercise of the over-allotment option of 4,500,000 Units[65] - The company also sold 890,000 Private Placement Units at $10.00 per Unit, generating gross proceeds of $8,900,000[42] - Transaction costs related to the Initial Public Offering amounted to $20,186,929, including a cash underwriting fee of $6,900,000[26] - The underwriters received an underwriting discount of $0.20 per Public Share, totaling $6,900,000, and an additional deferred commission of $12,075,000[74] Business Operations - The company has not yet commenced any operations and will not generate operating revenues until after completing its initial Business Combination[23] - The Company does not believe it will need to raise additional funds to meet operating expenditures prior to the initial Business Combination[44] - The company has not engaged in any operations or generated revenues to date, focusing instead on organizational activities and preparing for the Initial Public Offering[106] - The company expects to incur significant costs in pursuing acquisition plans, with no assurance of successful Business Combinations[105] Business Combination - The trust account holds $345,000,000 from the net proceeds of the Initial Public Offering, which will be used for a Business Combination[28] - The company must complete a Business Combination with an aggregate fair market value of at least 80% of the net assets held in the Trust Account[27] - The company has a Combination Period of 24 months to complete a Business Combination, extendable to 27 months under certain conditions[33] - The Company intends to use funds in the Trust Account to complete the Business Combination and for working capital to finance operations of the target business[112] Financial Performance - The net loss for the period from September 12, 2025, to September 30, 2025, was $56,679, resulting in a basic and diluted net loss per Class B ordinary share of $0.01[15] - As of September 30, 2025, the company reported a net loss of $56,679, primarily due to general and administrative costs[107] - The net loss per Class B ordinary share for the period from September 12, 2025, through September 30, 2025, was calculated based on the weighted average number of Class B ordinary shares outstanding[59] Shareholder Information - As of September 30, 2025, the Company had 8,625,000 Class B ordinary shares issued and outstanding, with up to 1,125,000 shares subject to forfeiture if the over-allotment option was not fully exercised[82] - The Company is authorized to issue 500,000,000 Class A ordinary shares, with none issued or outstanding as of September 30, 2025[81] - The Sponsor purchased 890,000 Private Placement Units for a total of $8,900,000 at $10.00 per Unit, which are identical to the Units sold in the Initial Public Offering[68] Loans and Financing - The Sponsor has agreed to provide Working Capital Loans up to $1,500,000, which may be converted into Private Placement Units at $10.00 per unit upon completion of a Business Combination[43] - The Sponsor agreed to loan the Company up to $300,000 for Initial Public Offering expenses, with $28,020 outstanding as of September 30, 2025[69] - The Company has no outstanding borrowings under Working Capital Loans as of September 30, 2025[71] - The Company does not expect to need additional funds for operating expenditures but may require financing for the Business Combination or share redemptions[115] Regulatory and Compliance - The Company is classified as an "emerging growth company" and is exempt from certain reporting requirements under the JOBS Act[45] - The Company accounted for Public Warrants and Placement Warrants as liabilities under FASB ASC Topic 815, as they do not meet the criteria for equity treatment[62] - There were no off-balance sheet arrangements as of September 30, 2025[116] Market and Economic Factors - Geopolitical tensions and tariffs may adversely affect the Company's search for an initial Business Combination and related target businesses[79] - The company is currently evaluating the impact of the One Big Beautiful Bill Act, but no significant impact on financial statements is expected[77]

Core Insights - Lumexa Imaging Holdings, Bluerock Acquisition, and Carbon Capital Partners collectively raised $913 million upon their NASDAQ debut on December 11 [1] - Lumexa Imaging Holdings opened at $18.65 per share, slightly above its offering price, and closed at $18.52, with a total market capitalization of $1.751 billion [1][4] - Lumexa Imaging reported revenues of $755 million and a net loss of $18.41 million for the nine months ending September 30, 2025 [4] New Listings - Lumexa Imaging Holdings (LMRI) raised $463 million by issuing 25 million shares at $18.50 each, with funds allocated for repaying existing loans and general corporate purposes [4] - Bluerock Acquisition (BLRKU) and Carbon Capital Partners (KBONU) also listed on the same day, raising $150 million and $300 million respectively [5] IPO Filings - Brand Meditech Limited, a Chinese company, filed for an IPO with plans to list on NASDAQ under the ticker AED, aiming to raise between $6.3 million and $8.1 million by offering 900,000 shares at $7 to $9 each [6][10] - Brand Meditech specializes in medical devices and software, including infusion pumps and portable X-ray machines, targeting various medical fields [10] Financial Data - For the fiscal years ending March 31, 2024, and 2025, Brand Meditech reported revenues of $2.619 million and $2.549 million, with net profits of $1.47 million and $1.21 million respectively [11]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Table of Contents Amendment No. 1 to FORM S-1 As filed with the U.S. Securities and Exchange Commission on October 15, 2025. Registration No. 333-290687 REGISTRATION STATEMENT Thomas F. Karam Chief Executive Officer 321 Biden Street, 12th Floor Scranton, Pennsylvania 18505 (Address, including zip code, and telephone number, including area code, of registrant's principal executive offices) Thomas F. Karam Chief Executive Officer 321 Bide ...

Table of Contents As filed with the U.S. Securities and Exchange Commission on October 2, 2025. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Karbon Capital Partners Corp. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Cayman Islands 6770 98-1883211 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Iden ...